Who We Are
Sarah Cannon Research Institute is the research arm of HCA’s global cancer institute, Sarah Cannon. Focused on advancing therapies for patients, it is one of the world’s leading clinical research organizations conducting community-based clinical trials throughout the United States and United Kingdom.
The organization has led more than 250 first-in-human clinical trials since its inception in 1993, and has been a clinical trial leader in the majority of approved cancer therapies in the last ten years.
Sarah Cannon Research Institute UK is a unique standalone trial facility that collaborates and works closely with clinical investigators to develop new and innovative cancer therapies for patients.
We are part of the HCA Healthcare UK network, which comprises six central London hospitals and an expert group of 60 oncologists making up our Leaders in Oncology Care (LOC), and specialise in the development of novel cancer therapies, providing a clinical research option for cancer patients in London and across the United Kingdom.
Sarah Cannon Research Institute UK is the first trials unit outside the NHS that has the ability to offer new anti-cancer drugs in clinical trials. As a dedicated trials unit we are focused on fast study set-up time lines to offer patients rapid access to new investigational drug therapies – importantly we are open for both private and NHS patients.
Learn more by reading our Patient Guide >>
Advancing therapies for patients
Sarah Cannon Research Institute UK aims to provide precision medicine for cancer patients through the development of targeted therapies that are not only directed towards the cancer cell, but a specific alteration within the cancer cell.
As part of our ‘Personalised Medicine Initiative’ we provide the necessary molecular testing to better understand why a patient's cancer is behaving the way it is. While it is important to understand the origin and location of cancer cells, it is also possible, through biopsy, to identify what is driving the tumour cells, as well as what mutations and genetic abnormalities are present that can be targeted. This knowledge can help the patient therapeutically.
We offer the ability to enrol patients in early and later stage clinical trials. A variety of cancers are currently being researched, including breast, lung, prostate and colorectal cancer, as well as some of the rarer blood cancers.
Who is Sarah Cannon?
Sarah Ophelia Colley Cannon (October 25, 1912 – March 4, 1996), known professionally as Minnie Pearl, was an American country comedienne. After battling breast cancer, she offered the use of her name to the HCA medical center in Nashville where she had been successfully treated. The center was later named the Sarah Cannon Cancer Center, and has been expanded to several other hospitals in the U.S. Her name has also been lent to Sarah Cannon Research Institute, part of the HCA family, for the conduct of oncology clinical trials.
Updated Infographic 17/03/17